Physicians divided over patient choice in biologics vs biosimilars

China’s physicians expressed the highest support amongst surveyed countries.

Physician attitudes toward patient involvement in choosing between biologics and biosimilars differ widely across global healthcare markets, according to GlobalData.

The report revealed nearly half (49%) of physicians support involving patients in treatment decisions. However, the level of support differs significantly by country.

In China, 85% of physicians expressed support for patient choice, the highest amongst surveyed countries.

Meanwhile, only 21% of physicians in Germany and 29% in France shared the same view.

The findings reflect deeper systemic and cultural differences that shape healthcare delivery and professional practices in each country, said Sachin Gharat, Associate Project Manager, Pharma at GlobalData.

“In markets like China, where healthcare reforms have actively promoted biosimilars, physicians may feel more confident in involving patients in these decisions,” the report said.